Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TDP2 | O95551 | 1/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14806795 | 0.83 | TDP2 (0.47) | ALDH1A1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL5154980 | 0.83 | TDP2 (0.47) | ALDH1A1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL13495402 | 0.77 | CYP2D6 (0.50) | ALDH1A1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL5031312 | 0.76 | MEN1 (0.52) | ALDH1A1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL30447750 | 0.76 | MEN1 (0.52) | ALDH1A1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL11872791 | 0.76 | CYP1A2 (0.59) | ALDH1A1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL9587960 | 0.76 | PTPRC (0.47) | ALDH1A1TDP2NSD2ABL1PLCG1 | |
| SCHEMBL13239508 | 0.75 | LMNA (0.48) | ALDH1A1MEN1BLMKMT2ACASP3 | |
| SCHEMBL8694805 | 0.74 | RXFP1 (0.58) | ALDH1A1MEN1KMT2AGAAKDM4E | |
| SCHEMBL14560536 | 0.73 | RXFP1 (0.57) | ALDH1A1KMT2AKDM4ESMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022133551-A1 | HISTONE DEACETYLASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-06-30 | — | — | WO | disclosed |
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| US-9981964-B2 | Maleimide derivatives as modulators of wnt pathway | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-05-29 | — | — | US | disclosed |
| EP-2978820-B1 | WAVELENGTH CONVERSION FILMS WITH MULTIPLE PHOTOSTABLE ORGANIC CHROMOPHORES | NITTO DENKO CORP (JP) | 2018-03-21 | — | — | EP | disclosed |
| EP-3083622-B1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY SCIENCE TECH & RES (SG) | 2018-03-21 | — | — | EP | disclosed |
| EP-3083622-B1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY SCIENCE TECH & RES (SG) | 2018-03-21 | — | — | EP | disclosed |
| EP-2788450-B1 | WAVELENGTH CONVERSION MATERIAL AS ENCAPSULANT FOR SOLAR MODULE SYSTEMS TO ENHANCE SOLAR HARVESTING EFFICIENCY | NITTO DENKO CORP (JP) | 2017-06-21 | — | — | EP | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2016-11-03 | — | — | US | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. | 2008-06-26 | — | — | US | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7332487-B2 | Nitrogen-containing 5-membered ring compound | TANABE SEIYAKU CO., LTD. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318926-A1 | MALEIMIDE DERIVATIVES AS MODULATORS OF WNT PATHWAY | WNT1, WNT3, CTNNB1 | ALDH1A1 779/4885TDP2 3885/4885NSD2 1910/4885 |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | GSK3B, GSK3A, PYGB | ALDH1A1 3907/4885TDP2 961/4885NSD2 4241/4885 |
| US-20080153821-A1 | Nitrogen-containing 5-membered ring compound | ALK, SCO2, NPR1 | ALDH1A1 2491/4885TDP2 3570/4885NSD2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.